Yan-Ruide Li

Jan 17, 2025 | nature.com | Yan-Ruide Li

AbstractThe clinical potential of current chimeric antigen receptor-engineered T (CAR-T) cell therapy is hampered by its autologous nature that poses considerable challenges in manufacturing, costs and patient selection. This spurs demand for off-the-shelf therapies.

Sep 23, 2024 | nature.com | Enbo Zhu |Jiaji Yu |Yan-Ruide Li |Feiyang Ma |Yang Liu |James Brown | +2 more

AbstractChimeric antigen receptor (CAR)-engineered T cells represent a front-line therapy for cancers. However, the current CAR T cell manufacturing protocols do not adequately reproduce immunological synapse formation. Here, in response to this limitation, we have developed a flexible graphene oxide antigen-presenting platform (GO-APP) that anchors antibodies onto graphene oxide.

Aug 14, 2024 | cell.com | Yan-Ruide Li |Lili Yang

Keywordschimeric antigen receptor-engineered T (CAR-T) cellsautoimmune diseaseautoreactive B cellsautoreactive T cellsimmunotherapycell therapyCAR-T cell therapy as emerging treatment for autoimmune diseasesCAR-T cell therapy has emerged as a revolutionary form of cancer immunotherapy [11. Larson, R.C. ∙ Maus, M.V.Recent advances and discoveries in the mechanisms and functions of CAR T cellsNat. Rev. Cancer. 2021; 21:145-161,22. Baker, D.J. ...